The acquisition of Euroflow, which makes pilot- and production-scale chromatography columns for the biotechnology industry, comes shortly after Pall bought the BioSepra Process Division from Ciphergen Biosystems last November for $32 million (€25m).
The company has been actively building a comprehensive chromatography business with product covering the breadth of the biopharmaceutical industry's focus, from early-stage discovery through to pilot and commercial-scale production. And its acquisitive stance suggests Pall is confident in the recovery - from earlier weakness - in its biopharmaceuticals business, which put in an 12 per cent hike in sales in the first quarter, reported last month.
Pall has held exclusive global marketing and distribution rights to Euroflow chromatography columns and associated technologies since 2002. The UK company's sales are currently about $5 million a year.
The chromatography market represents about 40 per cent of the total biotech industry potential for filtration and purification technologies.
Eric Krasnoff, Chairman and CEO of Pall, said the acquisition showed it was "responding to the industry's request for integrated systems solutions for purification technologies from development through large-scale production."